Q-omics provides the consensus-scored CALML4 profile across patient tissues and cancer cell-line models. CALML4 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CALML4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CALML4 RNA expression shows 19,621 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where CALML4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALML4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALML4 survival associations across molecular data types. CALML4 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALML4 RNA expression–survival associations across cancer types. High CALML4 expression shows unfavorable associations in KICH, LGG and BRCA, but favorable associations in MESO, STAD and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CALML4 RNA expression.
This table summarizes CALML4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CALML4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALML4 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, STAD, BLCA and LIHC. The KIRC box plot shows higher CALML4 RNA expression in tumor versus normal tissue (log2 FC = +0.992, t-test p < 0.001).
This table shows molecular features associated with CALML4 in patient tissues and cancer cell lines. In patient samples, CALML4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALML4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
